

1. **Name:** Christopher Paul Filson, MD, MS
  
2. **Office Address:** Department of Urology  
Emory University School of Medicine  
1365 Clifton Road, Building A (Suite 1400)  
Atlanta, Georgia 30322  
Tel (404) 778-8377  
Fax (678) 843-6693
  
3. **E-mail Address:** cfilson@emory.edu
  
4. **Citizenship:** United States
  
5. **Current Titles and Affiliations:**
  - a. Academic Appointments:
    - i. Primary Appointments: 2015 - Current  
Assistant Professor of Urology  
Emory University School of Medicine
    - ii. Joint and Secondary Appointments: 2015 - Current  
Staff Urologist  
Department of Urology  
Atlanta Veterans Administration Medical Center
  
6. **Previous Academic and Professional Appointments:**
  - Clinical Lecturer, Department of Urology 2013 – 2015  
University of California, Los Angeles
  - Clinical Lecturer, Department of Urology 2012 – 2013  
University of Michigan
  - Staff Urologist, Department of Urology 2012 – 2013  
Ann Arbor Veterans Administration Medical Center
  
7. **Previous Administrative and/or Clinical Appointments:**
  - Staff Urologist 2015 - 2015  
Northridge Hospital Medical Center
  - Staff Urologist 2013 – 2015  
Harbor-UCLA Medical Center
  - Staff Urologist (Fee-Basis) 2014 – 2015  
Greater Los Angeles Veterans Administration Medical Center

**8. Licensures/Boards:**

Georgia Composite Medical Board License #073548	2015 - Current
Medical Board of California License #A124743	2013 - Current

**9. Specialty Boards:**

American Board of Urology (eligible)	2017
--------------------------------------	------

**10. Education:**

B.A. in Molecular and Cell Biology (Emphasis in Immunology) University of California, Berkeley, CA	1997 – 2001
M.D., University of Michigan, Ann Arbor, MI	2002 – 2006
M.S. in Health and Health Care Research The Horace H Rackham School of Graduate Studies University of Michigan, Ann Arbor, MI	2009 – 2010

**11. Postgraduate Training:**

Intern, Department of General Surgery University of Michigan, Ann Arbor, MI, Paul Gauger, MD	2006 – 2007
Resident, Department of Urology University of Michigan, Ann Arbor, MI, Gary Faerber, MD	2007 – 2012
Health Services Research Fellowship Department of Urology, University of Michigan, Ann Arbor, MI (John T. Wei, MD, MS)	2009 – 2010
Health Services Research Fellowship Department of Urology, University of Michigan, Ann Arbor, MI (John T. Wei, MD, MS)	2012 – 2013
Urologic Oncology Fellowship Institute of Urologic Oncology, Department of Urology (David Geffen S.O.M. at UCLA, Los Angeles, CA) (Allan Pantuck, MD; Mark Litwin, MD, MPH)	2013 – 2015

**12. Committee Memberships:**

- a. National and International:  
Movember Global Action Plan 3 (GAP3) Working Group 2015 – present
- b. Institutional:  
Resident Education Committee 2008 – 2012  
Department of Urology, University of Michigan  
  
House Officers Association, Elected Representative 2010 – 2011  
University of Michigan Health System

**13. Peer Review Activities:**

- a. Manuscripts:  
Journal of Urology  
UROLOGY  
CANCER  
Journal of Endourology  
Prostate Cancer and Prostatic Diseases  
BJU International  
Urology Oncology: Seminars and Investigations  
World Journal of Urology  
Clinical Genitourinary Cancer

**14. Honors and Awards:**

- 1997 Dean's Honor List, University of California, Berkeley
- 1999 Dean's Honor List, University of California, Berkeley
- 2005 Dean's Annual Scholarship, University of Michigan Medical School
- 2006 Department of Urology Annual Medical Student Scholarship, University of Michigan Medical School
- 2006 Alpha Omega Alpha
- 2010 Honorable Mention for Best Presentation, Michigan Urologic Society Resident's Day
- 2010 Hamill-Bergmann Memorial Award (Most productive University of Michigan Research Resident)

**Society Memberships:**

- 2007 – present American Urological Association
- 2006 – 2013 American Urological Association, North Central Section
- 2013 – 2015 American Urological Association, Western Section

2015 – present American Urological Association, Southeastern Section  
2013 – present Society of Urologic Oncology  
2013 – present American Society of Clinical Oncology  
2015 – present Academy Health

**15. Formal Teaching:**

Medical Student Teaching:

Facilitator, Pre-matriculation Program, University of Michigan Medical School (2002) (120 hours)

**16. Lectureships, Seminar Invitations, and Visiting Professorships: This category includes talks given at your institution (e.g., grand rounds), as well as lectures at other academic venues.**

a. National and International:

Active Surveillance of Prostate Cancer: Current Landscape and Future Directions, NYU Department of Urology Grand Rounds, New York, NY, July 2014

Active Surveillance of Prostate Cancer: Current Landscape and Future Directions, University of California, Irvine, CA, August 2014

Active Surveillance of Prostate Cancer: Current Landscape and Future Directions, Emory University Department of Urology Grand Rounds, October 2014

b. Regional:

Renal Cell Carcinoma Case Presentations, UCLA Department of Urology State-of-the-Art Conference, Marina Del Rey, CA, March 2014

c. Institutional:

Regional Variation in Active Surveillance Among Men with Localized Prostate Cancer, Department of Urology Grand Rounds, University of Michigan, Ann Arbor, MI, June 2013

Treatment with anticholinergics combined with alpha-blockers for men with BPH: a meta-analysis. Division of Health Services Research Weekly Meeting, Department of Urology, University of Michigan, Ann Arbor, MI, November 2012

Lymphadenectomy for upper tract urothelial carcinoma, Department of Urology Grand Rounds, University of Michigan, Ann Arbor, MI, June 2011

Surgeon characteristics and long-term trends associated with adoption of laparoscopic radical nephrectomy. Department of Urology Nesbit Meeting, University of Michigan, Ann Arbor, MI, October 2010

**17. Abstract Presentations at National/International, Regional, and Institutional**

**Conferences:**

a. National and International:

1. **Filson CP\***, Castillo A, Kwan L, Litwin MS, Chamie K. Second primary malignancies: an analysis of SEER data. American Urological Association Annual Meeting, New Orleans, LA, USA, May 2015. (Poster)
2. **Filson CP\***, Laviana A, Tan HJ, Chamie K, Hu JC. Determinants of operative time for bladder cancer patients undergoing radical cystectomy. American Urological Association Annual Meeting, New Orleans, LA, USA, May 2015. (Poster)
3. **Filson CP\***, Margolis D, Huang J, Natarajan S, Lieu P, Dorey F, Marks LS. Should a normal multiparametric MRI preclude prostate biopsy? American Urological Association Annual Meeting, New Orleans, LA, USA, May 2015. (Poster)
4. **Filson CP\***, Margolis D, Huang J, Natarajan S, Lieu P, Dorey F, Reiter R, Marks LS. MR-US fusion biopsy to diagnose prostate cancer: first 1000 men at UCLA. American Urological Association Annual Meeting, New Orleans, LA, USA, May 2015. (Oral)
5. **Filson CP\***, Margolis D, Huang J, Natarajan S, Lieu P, Dorey F, Marks LS. MR-US fusion biopsy: importance of both systematic and targeted sampling to diagnose prostate cancer. American Urological Association Annual Meeting, New Orleans, LA, USA, May 2015. (Poster)
6. Tan HJ\*, Marks LS, Hoyt M, Kwan L, **Filson CP**, Macairan M, Lieu P, Litwin MS, and Stanton AL. Intolerance of uncertainty and urinary symptoms predict anxiety for men on active surveillance for low-risk prostate cancer. American Urological Association Annual Meeting, New Orleans, LA, USA, May 2015. (Poster)
7. **Filson CP\***, Lieu P, Margolis DJA, Natarajan S, Marks LS. Identification of focal therapy candidates among patients undergoing targeted MR-ultrasound fusion biopsy. 7<sup>th</sup> International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer. Pasadena, CA, August 2014. (Poster)
8. **Filson CP\***, Schroeck F, Ye Z, Wei JT, Hollenbeck BK, Miller DC. Variation in use of active surveillance among men undergoing expectant management of early-stage prostate cancer. American Urological Association Annual Meeting, Orlando, FL, USA, May 2014. (Oral)
9. Le J\*, **Filson CP**, Margolis DJ, Marks L. Use of MRI/US fusion for targeted prostate biopsy in active surveillance. American Urological Association Annual Meeting, Orlando, FL, USA, May 2014. (Oral)
10. **Filson CP\***, Schroeck F, Ye Z, Wei JT, Hollenbeck BK, Miller DC. Variation in use of active surveillance among men undergoing expectant management of early-stage prostate cancer. Society of Urologic Oncology Annual Meeting, Bethesda, MD, December 2013. (Poster)
11. **Filson CP\***, Boer B, Curry J, Linsell S, Ye Z, Montie JE, Miller DC. Improvement in clinical TNM staging documentation within a prostate cancer quality improvement collaborative. Society of Urologic Oncology Annual Meeting, Bethesda, MD, December

2013. (Poster)
12. **Filson CP\***, Hollingsworth JM, Wei JT. Trends and variation in medical management of men with benign prostatic hyperplasia and lower urinary tract symptoms (1993-2010). American Urological Association Annual Meeting, San Diego, CA, May 2013. (Poster)
  13. **Filson CP\***, Li A, Hollingsworth JM, Weizer AZ, et al. Patient recovery and quality of life after radical cystectomy: comparison of open versus robotic approaches. American Urological Association Annual Meeting, San Diego, CA, May 2013. (Poster)
  14. **Filson CP\***, Montgomery J, Dailey S, Crossley H, et al. Risk of complications of perioperative mitomycin (MMC) among bladder cancer patients undergoing endoscopic tumor resection. American Urological Association Annual Meeting, Atlanta, GA, May 2012. (Oral)
  15. Hollingsworth JM, Lai JC, Saigal CS, **Filson CP\***, Hollenbeck BK. Payments for outpatient urologic care in non-hospital based settings. American Urological Association Annual Meeting, Washington, DC, May 2011. (Oral)
  16. Hollingsworth JM, Lai JC, Saigal CS, **Filson CP\***, Hollenbeck BK. Do short-term outcomes following common urologic procedures vary by the ambulatory care setting where they were performed? American Urological Association Annual Meeting, Washington, DC, May 2011. (Oral)
  17. **Filson CP\***, Miller DC, Ruterbusch J, Colt JS, Chow WH, Schwartz K. Surgical approach and use of lymphadenectomy and adrenalectomy for patients with renal cell carcinoma. American Urological Association Annual Meeting, San Francisco, CA, May 2010. (Poster)
  18. **Filson CP\***, Dunn R, Miller DC. Short-term and off-label use of oral targeted therapy for patients with renal cell carcinoma. American Urological Association Annual Meeting, San Francisco, CA, May 2010. (Poster)
  19. **Filson CP\***, Miller DC, Ruterbusch J, Colt JS, Chow WH, Schwartz K. Use of nephron-sparing surgery among renal cell carcinoma patients with diabetes or hypertension. American Urological Association Annual Meeting, San Francisco, CA, May 2010. (Poster)
  20. **Filson CP\***, Ye Z, Miller DC. Use of partial nephrectomy in rural versus urban practice settings. American Urological Association Annual Meeting, San Francisco, CA, May 2010. (Poster)

**18. Research Focus:**

**19. Grant Support:**

**Previous Support:**

1. Co-Investigator (and Contributing Author) 2009 - 2013  
National Institutes of Health (5T32DK007782)

University of Michigan Training in Clinical Investigation in Urology,  
Understanding the Utilization and Costs of Targeted Therapies for Patients  
with Renal Cell Carcinoma  
Grant \$170,237

2. John and Suzanne Munn Endowed Research Fund 2009  
University of Michigan Comprehensive Cancer Center  
Grant \$30,000
  
3. American Urological Association (AUA) 2014 - 2015  
Urology Care Foundation Research Scholar Program  
Understanding Utilization of Expectant Management among Prostate Cancer Patients  
in an Integrated Delivery System  
Grant \$60,000
  
4. American Cancer Society 2015  
Postdoctoral Fellowship  
Understanding Surveillance Strategies for Veterans with Prostate Cancer  
Grant \$57,500

## 20. Bibliography:

### a. Published and Accepted Research Articles in Refereed Journals:

1. Tan HJ, **Filson CP**, Litwin MS. Contemporary age-based trends in the incidence of management of patients with early-stage kidney cancer. *Urol Oncol* 2015; **33**: e19-26.
2. Sonn GA, **Filson CP**, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ, Reiter RE, Marks LS. Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer. *Urol Oncol*. 2014; **32**: 952-957.
3. Hu JC, Treat E, **Filson CP**, McLaren I, Xiong S, Stepanian S, Hafez KS, Weizer AZ, Porter J. Technique and outcomes of robot-assisted retroperitoneoscopic partial nephrectomy: a multicenter study. *Eur Urol*. 2014; **66**: 542-549.
4. Banerjee M, **Filson CP**, Xia R, Miller DC. Logic regression for provider effects on kidney cancer treatment delivery. *Comp Mathematical Methods*. 2014; **2014**: 1-9.
5. **Filson CP**, Boer B, Curry J, Linsell S, Ye Z, Montie JE, Miller DC. Improvement in clinical TNM staging documentation within a prostate cancer quality improvement collaborative. *Urology*. 2014; **83**: 781-7.
6. **Filson CP**, Schroeck FR, Ye Z, Wei JT, Hollenbeck BK, Miller DC. Variation in use of active

- surveillance among men undergoing expectant management for early-stage prostate cancer. *J Urol*. 2014; 192: 75-81.
7. **Filson CP**, Wei JT, Hollingsworth JM. Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. *Urology*. 2013; 82: 1386-1392.
  8. **Filson CP**, Montgomery JS, Dailey SM, Crossley HS, Lentz H, Tallman C, He C, Weizer AZ. Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection. *Urol Oncol*. 2014; 32: e1-8.
  9. **Filson CP**, Hollingsworth JM, Clemens JQ, Wei JT. The efficacy and safety of combined therapy with alpha-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. *J Urol*. 2013; 190: 2153-2160.
  10. **Filson CP**, Miller DC, Colt JS, Ruterbusch J, Linehan WM, Chow WH, Schwartz K. Use of nephron-sparing surgery among renal cell carcinoma patients with diabetes and hypertension. *Urol Oncol*. 2014; 32: e15-21.
  11. Johnson EK, **Filson CP**, Faerber GJ, Park JM, Bloom DA, Wan J. Prospective tracking of pediatric urology consults: knowing is half the battle. *J Urol*. 2012; 187: 1844-1849.
  12. **Filson CP**, Banerjee M, Wolf JS Jr, Ye Z, Wei JT, Miller DC. Surgeon characteristics and long-term trends in the adoption of laparoscopic radical nephrectomy. *J Urol*. 2011; 185: 2072-2077.
  13. **Filson CP**, Miller DC, Colt JS, Ruterbusch J, Linehan WM, Chow WH, Schwartz K. Surgical approach and the use of lymphadenectomy and adrenalectomy among patients undergoing radical nephrectomy for renal cell carcinoma. *Urol Oncol*. 2012; 30: 856-863.
  14. **Filson CP**, Redman BG, Dunn RL, Miller DC. Initial patterns of care with the oral targeted therapies for patients with renal cell carcinoma. *Urology*. 2011; 77: 825-830.
  15. Miller DC, **Filson CP**, Wallner LP, Montie JE, Campbell DA, Wei JT. Comparing performance of Morbidity and Mortality Conference and National Surgical Quality Improvement Program for detection of complications after urologic surgery. *Urology*. 2006; 68: 931-937.
- b. Manuscripts Submitted:**
1. **Filson CP**, Shelton JB, Tan HJ, Kwan L, Skolarus TS, Saigal CS, Litwin MS. Expectant Management of Veterans with Early-Stage Prostate Cancer. Submitted to *CANCER*.
  2. **Filson CP**, Margolis DJA, Huang J, Natarajan S, Lieu P, Dorey FJ, Reiter RE, Marks LS. Diagnosing clinically significant prostate cancer with MR-US fusion biopsy: the UCLA experience. Submitted to *J Clin Oncol*.
  3. Li AY, **Filson CP**, Hollingsworth JM, He C, Weizer AZ, Hollenbeck BK, Gilbert SM, Hafez KS, Lee CT, Dunn RL, Wei JT, Montgomery JS. Patient recovery and quality of life after radical cystectomy: comparison of open versus robotic approaches. Submitted to



Urologic Oncology.

4. Tan HJ, Marks LS, Hoyt M, Kwan L, **Filson CP**, Macairan M, Lieu P, Litwin MS, and Stanton AL. Intolerance of uncertainty and urinary symptoms predict anxiety for men on active surveillance for low-risk prostate cancer. Submitted to Urologic Oncology.

**c. Review Articles:**

1. **Filson CP**, Marks LS, Litwin MS. Expectant management for men with early stage prostate cancer. *CA Cancer J Clin.* 2015; 65: 264-282.
2. Milose JC, **Filson CP**, Weizer AZ, Hafez KS, Montgomery JS. Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance. *Open Access J Urol.* 2011; 4: 1-8.
3. **Filson CP**, Hollingsworth JM, Skolarus TA, Clemens JQ, Hollenbeck BK. Health care reform in 2010: transforming the delivery system to improve quality of care. *World J Urol.* 2011; 29: 85-90.

**d. Book Chapters:**

1. **Filson CP**, Wei JT. Clinical Assessment and Diagnosis of Lower Urinary Tract Dysfunction (LUTD): United States. *Benign Prostatic Hyperplasia: Modern Clinical Care and Management.* 1st edition. Edited by Kaplan SA. Oxford. Wiley-Blackwell.
2. Koo J, **Filson CP**, Huang J, Pantuck A. Collecting duct carcinoma and renal medullary carcinoma. *The Kidney: A Comprehensive Guide to Pathologic Diagnosis and Management.* Edited by Hansel D, Paner G, Kane C, and Chang S. Springer Science.

**e. Published Abstracts:**

1. **Filson CP**, Castillo A, Kwan L, Litwin MS, Chamie K. Second primary malignancies: an analysis of SEER data. Accepted at American Urological Association Annual Meeting, May 2015, New Orleans, LA, USA.
2. **Filson CP**, Laviana A, Tan HJ, Chamie K, Hu JC. Determinants of operative time for bladder cancer patients undergoing radical cystectomy. *J Urol.* 194: abstract MP65-20, 2015.
3. **Filson CP**, Margolis D, Huang J, Natarajan S, Lieu P, Dorey F, Marks LS. Should a normal multiparametric MRI preclude prostate biopsy? *J Urol.* 194: abstract MP60-11, 2015.
4. **Filson CP**, Margolis D, Huang J, Natarajan S, Lieu P, Dorey F, Reiter R, Marks LS. MR-US fusion biopsy to diagnose prostate cancer: first 1000 men at UCLA. *J Urol.* 194: abstract PD30-11, 2015.
5. **Filson CP**, Margolis D, Huang J, Natarajan S, Lieu P, Dorey F, Marks LS. MR-US fusion biopsy: importance of both systematic and targeted sampling to diagnose prostate cancer. *J Urol.* 194: abstract MP11-05, 2015.

6. **Filson CP**, Schroeck F, Ye Z, Wei JT, Hollenbeck BK, Miller DC. Variation in use of active surveillance among men undergoing expectant management of early-stage prostate cancer. J Urol. 191: abstract MP58-15, 2014.
7. **Filson CP**, Montgomery J, Dailey S, Crossley H, et al. Risk of complications of perioperative mitomycin (MMC) among bladder cancer patients undergoing endoscopic tumor resection. J Urol 187 (suppl): abstract 1674, 2012.
8. **Filson CP**, Hollingsworth JM, Wei JT. Trends and variation in medical management of men with benign prostatic hyperplasia and lower urinary tract symptoms (1993-2010). J Urol 189 (suppl): abstract 143, 2013.
9. **Filson CP**, Li A, Hollingsworth JM, Weizer AZ, et al. Patient recovery and quality of life after radical cystectomy: comparison of open versus robotic approaches. J Urol 189 (suppl): abstract 441, 2013.
10. **Filson CP**, Miller DC, Ruterbusch J, Colt JS, Chow WH, Schwartz K. Surgical approach and use of lymphadenectomy and adrenalectomy for patients with renal cell carcinoma. J Urol 183 (suppl): abstract 721, 2010.
11. **Filson CP**, Dunn R, Miller DC. Short-term and off-label use of oral targeted therapy for patients with renal cell carcinoma. J Urol 183 (suppl): abstract 345, 2010.
12. **Filson CP**, Miller DC, Ruterbusch J, Colt JS, Chow WH, Schwartz K. Use of nephron-sparing surgery among renal cell carcinoma patients with diabetes or hypertension. J Urol 183 (suppl): abstract 1481, 2010.
13. **Filson CP**, Ye Z, Miller DC. Use of partial nephrectomy in rural versus urban practice settings. J Urol 183 (suppl): abstract 489, 2010.
14. Hollingsworth JM, Lai JC, Saigal CS, **Filson CP**, Hollenbeck BK. Payments for outpatient urologic care in non-hospital based settings. J Urol. 185 (suppl): abstract 319, 2011.
15. Hollingsworth JM, Lai JC, Saigal CS, **Filson CP**, Hollenbeck BK. Do short-term outcomes following common urologic procedures vary by the ambulatory care setting where they were performed? J Urol. 185 (suppl): abstract 319, 2011.
16. Le J, **Filson CP**, Margolis DJ, Marks L. Use of MRI/US fusion for targeted prostate biopsy in active surveillance. J Urol. 191 (suppl): abstract V6-06, 2014.
17. Tan HJ, Marks LS, Hoyt M, Kwan L, **Filson CP**, Macairan M, Lieu P, Litwin MS, and Stanton AL. Intolerance of uncertainty and urinary symptoms predict anxiety for men on active surveillance for low-risk prostate cancer. J Urol. 194: abstract MP27-15, 2015.

**f. Other Publications:**

1. **Filson CP**, Hollingsworth JM. Editorial comment. Urology. 2013; 82: 333-334.